Neurocrine Biosciences, Inc. (NBIX) stock analysis
Healthcare · Drug Manufacturers - Specialty & Generic
From the 10-K filed 2026-02-11
Business type: Franchise
How it makes money
Neurocrine Biosciences earns revenue primarily by selling specialty pharmaceuticals in the United States, led by INGREZZA and supplemented by CRENESSITY.
The company generates its income by commercializing FDA-approved treatments for under-addressed neurological, endocrine, and psychiatric conditions. INGREZZA, prescribed for tardive dyskinesia and chorea associated with Huntington's disease, serves as the dominant financial driver, bringing in $2.51 billion in 2025. CRENESSITY, launched in December 2024 for classic congenital adrenal hyperplasia, added $301.2 million in its first full year of sales. Profitability is primarily driven by total prescription volume and patient demand, which are partially offset by net price adjustments resulting from market access investments.
What protects it: the moat
Neurocrine Biosciences protects its market position through patents, regulatory exclusivity, and specialized distribution networks that tightly control product supply.
Management asserts that intellectual property rights and specialized distribution channels safeguard its commercial products from generic and competitive threats. The company distributes INGREZZA through a limited specialty network of select specialty pharmacies and wholesale distributors, while CRENESSITY relies on a single specialty pharmacy provider tailored to its rare disease focus. Management also relies on long-term commercial supply agreements with multiple third-party manufacturers to maintain adequate raw material and active pharmaceutical ingredient supply.
What growth costs
The company continuously reinvests capital into extensive research and development programs, payroll, and a specialized sales force to expand its product pipeline.
Neurocrine Biosciences allocates substantial financial resources to maintain and grow its operations, spanning early-stage research, mid- to late-phase clinical trials, and commercial infrastructure. In 2025, total research and development expenses reached $1.02 billion, representing 35.5% of total revenues, driven by investments in Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia, alongside discovery efforts in endocrinology, metabolic disease, and biologics. Additionally, the company funds a specialized sales force of approximately 600 professionals to accelerate product penetration.
What could damage it
A severe disruption or loss of relationship with the limited third-party suppliers manufacturing INGREZZA and CRENESSITY could impair commercialization and reduce earnings.
Because Neurocrine Biosciences owns no internal manufacturing capabilities, it relies entirely on third-party manufacturers and suppliers for active pharmaceutical ingredients and finished product production. If these third-party partners fail to devote sufficient time and resources, experience manufacturing delays, or suffer compliance failures under current Good Manufacturing Practice standards, the company's ability to supply its approved drugs would be severely compromised, directly harming revenue generation.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.